You are here

  • Home
  • Archive
  • Volume 12, Issue 3
  • Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)

 

Online download statistics by month:

Online download statistics by month: March 2024 to July 2025

AbstractFullPdf
Mar 2024688690249
Apr 2024314316160
May 202420420497
Jun 202419920165
Jul 202411911972
Aug 2024929252
Sep 2024818161
Oct 2024717251
Nov 202411711873
Dec 2024848748
Jan 202510510570
Feb 202528528558
Mar 202510210270
Apr 202510510651
May 2025656539
Jun 2025363924
Jul 2025110
Total266826831240